• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Brentuximab Vedotin
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    Adcetris 50 mg
    Takeda
    RX
    partial basket chart
    Adcetris 50 mg

    Monoclonal Antibody. Brentuximab Vedotin 50 mg.
    VIAL (Pwdr. for conc. for solution for IV infus.): 1 x 50 mg. The recom. dose is 1.8 mg/kg administ. as an IV infus. over 30 min. every 3 wks. If the pt. weight >100 kg, the dose calcul. should use 100 kg. Tmt. should be cont. until dis. progress. or unaccep.tox. Pts. who achieve stab. dis. or better should receive a minim. of 8 cycles and up to a max. of 16 cycles (approx. 1 year). Pts. with CTCL should receive up to 16 cyclesDose should be individ. ajust in pts. with new or worsen. periph. sens./motor neuropath., neutpropen. The recomm. start.  dose in pts with sev. renal impair or hep.  impair. is 1.2 mg/ kg admin. as IV infus. over 30 min. every 3 wks. See lit.
    Tmt. of adult pts. with relapsed or refractory CD30+ Hodgkin lymphoma (HL). Follow. autologous stem cell transplant (ASCT) or follow. at least two prior therapies when ASCT or multi-agent chemother. is not a tmt. option. Tmt. of adult pts. with CD30+ HL at incr. risk of relapse or progress. follow. ASCT. Tmt. of adult pts. with relapsed or refract. system. anaplastic large cell lymphoma (sALCL). Tmt. of adult pts. with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior syst.  ther.
    C/I: Hypersens., comb. use with Bleomycin.

    CLOSE